Global Allogeneic Cell Therapy Market Report 2023: Sector is Expected to Reach $1.72 billion by 2030 at a CAGR of 27.4% - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Allogeneic Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (Stem Cell, Non-stem Cell), By Therapeutic Area (Hematological Disorders, Dermatological Disorders), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global allogeneic cell therapy market size is expected to reach USD 1.72 billion by 2030, expanding at 27.40% CAGR from 2023 to 2030.

Companies Mentioned

• SSM Cardinal Glennon Children's Medical Center
• Cleveland Cord Blood Center
• Duke University School of Medicine
• New York Blood Center
• Clinimmune Labs, University of Colorado Cord Blood Bank
• MD Anderson Cord Blood Bank
• LifeSouth Community Blood Centers, Inc.
• Bloodworks Northwest
• JCR Pharmaceuticals Co., Ltd.
• Sumitomo Pharma Co., Ltd.
• Atara Biotherapeutics
• Mallinckrodt Pharmaceuticals
• Tego Science Inc.
• Takeda Pharmaceutical Company Limited.
• STEMPEUTICS RESEARCH PVT LTD.
• Biosolution Co., Ltd.
• MEDIPOST Co., Ltd.

Allogeneic cell therapy involves transferring cells from healthy donors to patients to treat chronic diseases such as cancer and cardiovascular diseases. The donor cells can be directly administered to genetically similar patients or added to a cell bank.

The therapies are typically produced in large batches from different donor tissues like bone marrow, and the manufacturing process is similar to that used for protein drugs and other large-scale derived materials. Allogeneic cell therapies offer several benefits over autologous therapies, including being less expensive and their availability as a scalable off-the-shelf product. As a result, the adoption of such therapies is increasing with several biotechnology companies conducting clinical trials treatment of various diseases.

There has been a significant increase in the number of allogeneic cell-based therapy clinical trials in recent years. According to the US National Institutes of Health, the number of mesenchymal stem cell (MSC) based clinical trials using cellular therapy has doubled over the last five years, with 1014 MSC-based clinical trials registered in the government database as either completed or in the process as of July 14th, 2021. This growth in clinical trials, combined with advancements in precision medicine and increased cell therapy production facilities is expected to drive market growth in the coming years.

The rising number of regulatory approvals for allogeneic cell-based therapies is expected to boost market growth over the forecast period. For instance, in October 2021, Enzyvant was granted FDA approval for its RETHYMIC, a single-dose regenerative tissue-based therapy for immunological reconstitution in pediatric patients with congenital athymia.

Moreover, in August 2022, Charles River Laboratories received approval from the European Medicines Agency (EMA) for its Memphis cell therapy manufacturing facility, which will enable the commercial production of allogeneic cell therapy. This approval is another significant milestone for the market, as it opens up new possibilities for treating various chronic diseases.

Allogeneic Cell Therapy Market Report Highlights

• The stem cell therapies segment held the largest share of 77.00% in 2022. Allogeneic stem cell therapy is most frequently used to treat chronic diseases like blood cancers, leukemia, and lymphoma as well as specialized blood or autoimmune disorders
• By therapeutic area, the hematological disorders segments accounted for the largest share of 58.22% in the global allogeneic cell therapy industry in 2022. Since leading market players are implementing several strategic plans into action to create cutting-edge allogeneic cell therapies for hematological disease treatment
• North America held the largest market share of 80.42% in 2022. This can be attributed to the presence of the major global players in the market, and growing investments from public and private organizations for proteomic and life science research in the region

Key Attributes:

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope

3.2. Market Lineage Outlook

3.3. Market Dynamics

3.3.1. Market Driver Analysis

3.3.1.1. Rising prevalence of chronic and infectious diseases

3.3.1.2. Increasing FDA approvals of allogeneic cell therapies

3.3.1.3. Increasing government funding for stem cell therapies

3.3.2. Market Restraint Analysis

3.3.2.1. High research costs and challenges with immune rejection

3.4. Industry Analysis Tools

3.5. Pipeline Analysis

3.6. COVID-19 Impact Analysis

Chapter 4. Allogeneic Cell Therapy Market: Therapy Type Business Analysis

Chapter 5. Allogeneic Cell Therapy Market: Therapeutic Area Business Analysis

Chapter 6. Allogeneic Cell Therapy Market: Regional Business Analysis

Chapter 7. Competitive Landscape

7.1. Company Categorization

7.2. Strategy Mapping

7.3. Company Profiles/Listing

For more information about this report visit https://www.researchandmarkets.com/r/6w79t3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900